Trading was light with 42K shares changing hands in the last trading session. Volume was down 77.26% under the stocks average daily volume.
Short traders are feeling a little more bearish on shares of the company recently if you evaluate the motion in short interest. The firm saw a rise in short interest of 158.71% as of October 13, 2017 from the last reporting period. Short shares grew 152,898 over that period. With short interest at 249,235 and short average daily volume at 299,932, days to cover is 1.0 and the short interest percentage is 0.01% as of October 13.
A few notable investment firms have updated their holdings. Citadel Advisors LLC grew its position by buying 43,435 shares an increase of 181.7% from 09/30/2016 to 03/31/2016. Citadel Advisors LLC now holds 67,345 shares with a value of $64,000. The value of the position overall is up by 204.8%.
The company is now down since yesterday’s close of $2.20. It is currently trading at $2.20 barely above $2.04, the 50 day moving average and a tad higher than the 200 day moving average of $2.06. The 50 day moving average went up by +7.7894% whereas the 200 day average was up by +6.6482%.
Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunotherapeutic products for the treatment of cancer. Its lead product candidate is IMP321, a recombinant protein, which is in phase II clinical trials in metastatic breast cancer when used as a chemo-immunotherapy. The company’s other products include IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. It also develops CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. The company has collaboration with NEC Corporation and Yamaguchi University. Prima BioMed Ltd. is based in Sydney, Australia..